Lisata Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LSTA research report →
Price Chart
About the company
Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on pioneering and bringing to market cellular therapies. These treatments are designed to either reverse disease progression or facilitate the repair of damaged bodily tissues.
- CEO
- David J. Mazzo
- IPO
- 1999
- Employees
- 21
- HQ
- Basking Ridge, NJ, US
Get TickerSpark's AI analysis on LSTA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $9.71M
- P/E
- -0.48
- PEG
- -0.06
- P/S
- 97.12
- P/B
- 0.01
- EV/EBITDA
- 12.47
- Div Yield
- 0.00%
- Gross Margin
- 91.00%
- Op Margin
- -22043.00%
- Net Margin
- -17159.00%
- ROE
- -10.97%
- ROIC
- -2.55%
Latest fiscal year · YoY change
- Revenue
- $170.00K-83.0%
- Gross Profit
- $24.00K-97.6%
- Op Income
- $-18,209,000
- Net Income
- $-16,586,000+17.0%
- EPS
- $-1.91+20.4%
- OCF Growth
- +17.6%
- FCF Growth
- +17.5%
- 52W High
- $5.07
- 52W Low
- $0.85
- 50D MA
- $1.22
- 200D MA
- $2.79
- Beta
- 0.80
- RSI (14)
- 38
- Avg Volume
- 311.11K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Lisata reported a smaller third-quarter loss, ended the period with $19 million in cash, and said multiple positive certepetide data readouts plus new partnerships keep it on track toward a data- and transaction-heavy 2026.· November 6, 2025
- Operating expenses fell 17.3% year over year to $4.4 million, and net loss improved to $4.2 million from $4.9 million.
- Cash and cash equivalents were about $19 million at September 30, 2025, with runway projected into the first quarter of 2027.
- Management highlighted positive preliminary data from ASCEND, iLSTA, and CENDIFOX, with final ASCEND and iLSTA data expected in the first quarter of 2026.
- Lisata signed a nonexclusive global license with Catalent and a strategic alliance with GATC Health to broaden certepetide’s potential applications.
- The company is preparing for a potential Phase III path for ASCEND, but says funding will likely require partners rather than unilateral self-funding.
For the three months ended September 30, 2025, operating expenses were $4.4 million versus $5.3 million a year ago, a decrease of $0.9 million, or 17.3%. Research and development expense was about $2.0 million versus $2.5 million, down $0.6 million, or 22.9%, and general and administrative expense was about $2.5 million versus $2.8 million, down $0.3 million, or 12.1%. Net loss was $4.2 million compared with $4.9 million in the prior-year quarter. Cash and cash equivalents were approximately $19 million as of September 30, 2025, and the company said current funds should support operations into the first quarter of 2027. Management did not provide revenue or EPS, and no formal next-quarter or full-year financial guidance was given.
David Mazzo said the quarter was active and productive, with Lisata advancing certepetide across multiple studies and broadening the pipeline through business development. He pointed to encouraging preliminary data from ASCEND, iLSTA, and CENDIFOX as corroboration of certepetide’s potential across several cancer regimens. His tone was optimistic but pragmatic: he stressed that the company is preparing for Phase III, but that a partnership-driven financing approach is likely necessary in the current market.
James Nisco emphasized disciplined spending and capital preservation. He said operating expenses declined to $4.4 million, driven by lower R&D spend on chemistry, manufacturing and controls and lower clinical expenses, plus lower G&A from reduced consulting and headcount. He also reiterated that the $19 million cash balance and planned activities should fund the business into the first quarter of 2027, reflecting what he called prudent capital management and expense minimization.
Analysts focused on timing and financing. On CENDIFOX, management said it could not give a precise date for the next data cut because the timing is controlled by the University of Kansas investigator; for GBM, management said enrollment is about two-thirds complete toward the 30-patient target. Questions about the cash runway and ASCEND Phase III funding led management to say the runway does not assume a Phase III ASCEND trial and that any Phase III would likely require partners or licensees, not solo funding, because a unilateral raise would be too dilutive.
The call highlighted multiple clinical signals that management believes support certepetide’s potential, including positive trends in survival and response endpoints across ASCEND, iLSTA, and CENDIFOX. Management also cited new nonexclusive partnering activity with Catalent and GATC, plus a newly issued U.S. patent extending protection to March 2040, as evidence of expanding commercial optionality.
The main risk is funding: management acknowledged that a Phase III ASCEND program would require substantial capital and likely outside partners, especially in a difficult small-cap biotech financing environment. Several updates still depend on investigator-led or third-party timelines, including CENDIFOX and Qilu’s pancreatic cancer study, so key data and next steps remain uncertain.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 75.5%
- Shares Outstanding
- 10.80M
- Float Shares
- 8.15M
of shares held by institutions
31 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Adage Capital Partners Gp, L.L.C. | 2.49M | ▲ 2.49M |
| Trv Gp V, LLC | 455.19K | ▲ 455.19K |
| Seven Fleet Capital Management LP | 371.41K | ▲ 371.41K |
| Fcpm Iii Services B.V. | 297.48K | ▲ 297.48K |
| Vanguard Capital Management LLC | 278.84K | 0 |
| Vanguard Group Inc | 270.91K | ▲ 395 |
| Alpha Wave Global, LP | 183.32K | ▲ 183.32K |
| Sofinnova Investments, Inc. | 156.46K | ▲ 156.46K |
| Venbio Partners LLC | 156.46K | ▲ 156.46K |
| Yakira Capital Management, Inc. | 135.52K | ▼ 3.04K |
| Nantahala Capital Management, LLC | 101.22K | ▲ 101.22K |
| Citadel Advisors LLC | 76.28K | ▲ 60.73K |
Held by 24 ETFs
Biggest fund positions in LSTA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 13, 26 | Farrow Jeffrey S | other | 0 |
| Sep 17, 26 | LOVE TED W | other | 0 |
| Sep 17, 26 | LOVE TED W | other | 0 |
| Sep 17, 26 | Lehrer-Graiwer Joshua | other | 0 |
| Sep 17, 26 | Lehrer-Graiwer Joshua | other | 0 |
| Sep 17, 26 | Lehrer-Graiwer Joshua | other | 0 |
| Sep 17, 26 | Lehrer-Graiwer Joshua | other | 0 |
| Sep 17, 26 | Lehrer-Graiwer Joshua | other | 0 |
| Sep 17, 26 | Lehrer-Graiwer Joshua | other | 0 |
| Sep 17, 26 | Lehrer-Graiwer Joshua | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our LSTA coverage
Recent articles, reports, and earnings notes.
No research on LSTA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate LSTA report →Lisata Therapeutics, Inc. Announces Reverse Stock Split Effective November 23, 2026
globenewswire.com · Nov 19
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces MAR001 Reduces Triglycerides Without Worsening Glycemic Control in Phase 2b TYDAL-TIMI 78 Trial; Results Presented as AHA 2026 Late-Breaker and Published in The New England Journal of Medicine
globenewswire.com · Nov 9
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, to Participate in Upcoming November Investor Conferences
globenewswire.com · Nov 5
INVESTIGATION ALERT - The M&A Class Action Firm Is Investigating the Merger - LFCR, LSTA, FSHP and BWIN - IS IT A FAIR DEAL FOR YOU?
prnewswire.com · Nov 3
Lisata adds biopharma finance veteran Jeffrey Farrow to board
proactiveinvestors.com · Oct 15
Financial Survey: Lisata Therapeutics (NASDAQ:LSTA) vs. Dyadic International (NASDAQ:DYAI)
defenseworld.net · Oct 15
Lisata Therapeutics Appoints Jeff Farrow to Board of Directors
globenewswire.com · Oct 14
Head to Head Analysis: GeoVax Labs (NASDAQ:GOVX) vs. Lisata Therapeutics (NASDAQ:LSTA)
defenseworld.net · Oct 11
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.